On Nov. 30 the FDA approved a Phase III clinical trial to confirm the effectiveness of treating post-traumatic stress disorder (PTSD) with MDMA, also known as Ecstasy. This news appeared in headlines throughout the world, as it represents an important – yet somewhat unorthodox – advance in PTSD trea...